Notably, two independent studies revealed the co-treatment with proteasome inhibitors (Bortezomib or Carfilzomib) boost the efficiency of anti-B cell maturation antigen (anti-BCMA) Chimeric antigen receptor T (CAR-T) cell in multiple myeloma animal model and human patients via blocking the proteasome mediated degradation of BCMA to stabilize its in cell membrane 93, 94. Here, TNFRSF17 is linked to AL amyloidosis.